hVIVO buys CRS Berlin as expands into dermatology and women's health
(Alliance News) - hVIVO PLC on Thursday announced the acquisition of a clinical research unit to expand its expertise into dermatology and women's health markets. Read More
| Price | 6.90p on 03-09-2026 at 18:15:13 |
|---|---|
| Change | 0.00p 0% |
| Buy | 7.10p |
| Sell | 6.70p |
| Last Trade: | Sell 5,050.00 at 6.815p |
| Day's Volume: | 623,330 |
| Last Close: | 6.90p |
| Open: | 6.90p |
| ISIN: | GB00B9275X97 |
| Day's Range | 6.90p - 6.90p |
| 52wk Range: | 4.35p - 10.10p |
| Market Capitalisation: | £47.50m |
| VWAP: | 6.988488p |
| Shares in Issue: | 688.40m |
Sector: Health Care and Related Services
Listed In: FTSE AIM 100, FTSE AIM All-Share,
hVIVO (HVO) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 5,050 | 6.815p | Ordinary |
15:52:52 - 03-Sep-26 |
| Buy* | 20,000 | 7.03p | Ordinary |
15:50:27 - 03-Sep-26 |
| Buy* | 9,753 | 7.03p | Ordinary |
15:45:49 - 03-Sep-26 |
| Buy* | 4,000 | 7.00p | Ordinary |
14:56:17 - 03-Sep-26 |
| Sell* | 19,535 | 6.7302p | Ordinary |
14:21:13 - 03-Sep-26 |
| Buy* | 4,162 | 7.04p | Ordinary |
14:20:06 - 03-Sep-26 |
| Sell* | 2,504 | 6.866p | Ordinary |
14:08:33 - 03-Sep-26 |
| Sell* | 539 | 6.866p | Ordinary |
14:07:41 - 03-Sep-26 |
| Buy* | 2,353 | 7.04p | Ordinary |
14:06:52 - 03-Sep-26 |
| Sell* | 1,152 | 6.866p | Ordinary |
14:06:19 - 03-Sep-26 |
hVIVO (HVO) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 27th Aug 2026 7:00 am | RNS | hVIVO acquires CRS Berlin |
| 23rd Jul 2026 7:00 am | RNS | H1 2026 Trading Update |
| 13th Jul 2026 7:00 am | RNS | Change of Auditor |
| 9th Jun 2026 7:00 am | RNS | Holding(s) in Company |
| 1st Jun 2026 12:00 pm | RNS-R | Consultancy contract with Decoy Therapeutics |
| 29th May 2026 7:00 am | RNS | Grant of awards under Long Term Incentive Plan |
| 20th May 2026 7:00 am | RNS | Capital Markets Day |
| 13th May 2026 1:40 pm | RNS | Result of AGM |
| 12th May 2026 9:45 am | RNS | Holding(s) in Company |
| 7th May 2026 7:00 am | RNS | £6m Influenza HCT contract signed |